Vor Biopharma (VOR) Reiterated at Buy by Stifel After Meetings About Telitacicept Potential
Tweet Send to a Friend
Stifel analyst Stephen Willey reiterated a Buy rating and $40.00 price target on Vor Biopharma, Inc. (NASDAQ: VOR).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
